Compare · DGX vs HUM
DGX vs HUM
Side-by-side comparison of Quest Diagnostics Incorporated (DGX) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DGX and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $45.67B, about 1.7x DGX ($26.11B).
- Over the past year, DGX is up 25.0% and HUM is up 56.0% - HUM leads by 31.0 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- Quest Diagnostics Incorporated
- Humana Inc.
- Price
- $236.14-0.09%
- $398.16+4.72%
- Market cap
- $26.11B
- $45.67B
- 1M return
- -3.63%
- +1.83%
- 1Y return
- +25.03%
- +55.99%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 25
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest DGX
- Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
- Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
- Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
- Apple Health app Users to be Able to Order Labs from Quest Diagnostics
- CEO and President Davis J. E. sold $2,427,200 worth of shares (10,000 units at $242.72) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 122,423 units (SEC Form 4)
- SVP & General Counsel Prevoznik Michael E exercised 22,677 shares at a strike of $112.17, sold $5,513,083 worth of shares (22,677 units at $243.11) as part of a pre-agreed trading plan and gifted 1,000 shares, decreasing direct ownership by 3% to 36,557 units (SEC Form 4)
- Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
- Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com
- Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
- Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Latest HUM
- Humana upgraded by Barclays with a new price target
- New Humana research finds association between pharmacy care coordination services and improved health outcomes for cancer patients
- Humana Community Day 2026 Generates 2.2 Million Meals and Community Investments Nationwide
- New Study Links Integrated Specialty Pharmacy Care to Faster Access and Lower Costs
- Chief Medical Officer Nundy Shantanu was granted 2,549 units of Humana Common (SEC Form 4)
- Humana Earns 2026 Great Place To Work Certification™ and PEOPLE Companies That Care® Recognition
- Humana Board Declares Payment of Quarterly Dividend to Stockholders
- Humana Foundation Names 2026 Scholarship Recipients
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- New insider Nundy Shantanu claimed no ownership of stock in the company (SEC Form 3)